Astellas Pharma Inc. has completed its tender for Ocata Therapeutics, a biotechnology company focused on the research and development of regenerative medicines, primarily cell therapies, for approximately $379 million. Astellas had announced that it was acquiring Ocata in November 2015.

Astellas acquired Ocata through Laurel Acquisition Inc., a wholly owned subsidiary of Astellas US Holding, Inc. Laurel made a tender offer for all outstanding shares of common stock of Ocata, for a price of $8.50 per share in cash. Laurel was merged into Ocata, and Ocata ceased to be traded as a separate company

Source: Astellas Pharma